Knowledge of amino acid metabolism is critical to human health and has significant industrial applications as well. This study proposes to develop a coproduct method for the production of L-lysine, an essential amino acid of great economic and industrial importance. If successful, the L-lysine produced as a result of this study will be a coproduct of the erythromycin fermentation using Saccharopolyspora erythraea. Currently, L-lysine is produced from dedicated Corynebactium glutamicum fermentations, and as such, has costs associated with its production that are not absorbed through the production of a primary fermentation product. L-lysine produced as a coproduct from the erythromycin fermentation would be substantially less expensive to produce, and large quantities could be produced using this method because the erythromycin fermentation is also a very large-scale process. In addition, this study also proposes to investigate the potential for developing a dedicated fermentation method for L-cysteine production, using an erythromycin non-producing variant of S. erythraea. Until recently there was no need for fermentation-produced L-cysteine; but due to recent government regulations against the use of animal derived L-cysteine, the market for fermentation-produced material has grown significantly. The model organism used in this study is the erythromycin producing organism, S. erythraea, a bacterium that has been the subject of over 50 years of intensive genetic and biochemical research, providing a solid foundation upon which to build commercial processes for amino acid production.
Public Health Relevance: Prion diseases, or transmissible spongiform encephalopathies (TSEs), are a family of rare progressive neurodegenerative disorders that affect both humans and animals. Prion diseases are usually rapidly progressive and always fatal. This project aims to reduce the risk of acquiring TSE
Public Health Relevance Statement: 1 Project Narrative Prion diseases, or transmissible spongiform encephalopathies (TSEs), are a family of rare progressive neurodegenerative disorders that affect both humans and animals. Prion diseases are usually rapidly progressive and always fatal. This project aims to reduce the risk of acquiring TSE¿s in the population through the development of a biotechnological process for the production of amino acids that are used by humans and are currently obtained from possibly contaminated animal sources. page 1*
NIH Spending Category: Bioengineering; Brain Disorders; Emerging Infectious Diseases; Infectious Diseases; Neurodegenerative; Transmissible Spongiform Encephalopathy (TSE)
Project Terms: Affect; Amino Acids; Amino Acids, Essential; Animal Feed; Animal Model; Animal Models and Related Studies; Animal Sources; Animals; Assay; Bacteria; Bioassay; Biochemical; Biologic Assays; Biological Assay; Biotechnology, Genetic Engineering; Capital; Chemicals; Clinical Trials, Phase I; Cost Savings; Cysteine; Cystine; Data Banks; Data Bases; Databank, Electronic; Databanks; Database, Electronic; Databases; Degenerative Diseases, Nervous System; Degenerative Neurologic Disorders; Development; E coli; E-Mycin; Early-Stage Clinical Trials; Economics; Engineering; Engineerings; Equipment; Ery-Tab; Eryc; Eryderm; Erythro; Erythrocin; Erythromycin; Erythromycin A; Escherichia coli; Essential Amino Acids; Family; Fermentation; Figs; Figs - dietary; Foundations; Genes; Genetic; Genetic Alteration; Genetic Change; Genetic Engineering; Genetic defect; Goals; Government regulations; Half-Cystine; Health; Human; Human, General; Ilotycin; Intention; Intermediary Metabolism; Investigators; Knock-out; Knockout; Knowledge; L-Cysteine; L-Cystine; L-Lysine; Letters; Libraries; Licensing; Liquid substance; Lysine; METBL; Man (Taxonomy); Man, Modern; Manufacturer; Manufacturer Name; Marketing; Metabolic; Metabolic Processes; Metabolism; Methods; Modeling; Molecular Biology, Genetic Engineering; Motivation; Mutation; Neurodegenerative Diseases; Neurodegenerative Disorders; Neurologic Degenerative Conditions; Neurologic Diseases, Degenerative; Operation; Operative Procedures; Operative Surgical Procedures; Organism; Pediamycin; Phase; Phase 1 Clinical Trials; Phase I Clinical Trials; Phase I Study; Plasmids; Population; PrP Proteins; Prion Disease Pathway; Prion Diseases; Prion Protein Diseases; Prion Proteins; Prion-Induced Disorder; Prions; Process; Production; RP-Mycin; Recombinant DNA Technology; Recovery; Reporting; Reproduction spores; Research; Research Personnel; Researchers; Resistance; Risk; Robimycin; Route; Saccharopolyspora; Saccharopolyspora erythraea; Saving, Cost; Screening procedure; Solid; Spongiform Encephalopathies, Transmissible; Spores; Staging; Stream; Surgical; Surgical Interventions; Surgical Procedure; Technology; Transmissible Dementias; Variant; Variation; aminoacid; animal food; clinical data repository; clinical data warehouse; cost; cysteine desulfurase; data repository; dimer; essential amino acid; essential aminoacid; feeding; flasks; fluid; genome mutation; improved; interest; liquid; living system; lysine analog; manufacturing process; model organism; mutant; neurodegenerative illness; phase 1 study; phase 1 trial; phase I trial; protocol, phase I; public health relevance; relational database; resistant; screening; screenings; spongiform degeneration; spongiform encephalopathy; surgery; tool
